Artikel
Effect of Transdermal Magnesium Chloride on Quality of Life in Patients with Fibromyalgia – A Pilot Study
Suche in Medline nach
Autoren
-
Dietlind Wahner-Roedler
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
-
Deborah Engen
- Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA
-
Samantha McAllister
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
-
Mary Whipple
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
-
Ann Vincent
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
-
Stephen Cha
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
-
Brent Bauer
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
-
Dion Liza
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
| Veröffentlicht: | 1. September 2015 |
|---|
Gliederung
Text
Introduction: Fibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, sleep disturbances, and poor concentration. The primary cause of fibromyalgia remains unclear. Several reports suggest that fibromyalgia is an oxidative stress disorder and that deficiency in trace elements and antioxidants play an important role in the development of fibromyalgia. Magnesium is a trace element that is important for many metabolic functions. Several studies have reported intracellular magnesium levels to be decreased in fibromyalgia patients, and found a negative correlation between magnesium levels and fibromyalgia symptoms.
The objective of this study was to gather preliminary data on whether transdermal Magnesium Chloride can improve quality of live in women with fibromyalgia.
Methods: 40 female patients who were diagnosed with fibromyalgia at the Mayo Clinic Fibromyalgia Clinic were enrolled in the study. Each participant was provided with a spray bottle containing a trandermal magnesium solution and asked to apply 4 sprays per limb 2 times/day (400 mg of Magnesium Chloride/day) for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire (FIQ-R), at baseline, at 2 weeks and at 4 weeks. Data were analyzed using intent to treat as well as per protocol analysis. P< 0.05 was considered as statistically significant.
Results: 24 patients completed the study (9 dropped out due to skin irritation) and returned all followup measures. On average, participants were 57.2 years of age, (SD 7.6), were white (95%) and had a mean BMI of 31.3 kg /m2. Using intention to treat analysis by replacing missing values due to dropouts with the patient's previous score, FIQ-R subscale and total scores were significantly improved at 2 weeks and 4 weeks (total score: p=0.0001). Per-protocol analysis results were similar revealing that all subscales of the FIQ-R were significantly improved at 2 and 4 weeks (total score: p=0.0012)
Conclusion: This pilot study suggests that transdermal Magnesium Chloride applied twice a day on upper and lower limbs may be beneficial to patients with fibromyalgia. To our knowledge this is the first study evaluating the effectiveness and feasibility of using transdermal Magnesium Chloride for treatment of fibromyalgia symptoms.
